Background and Objectives: Gastric cancer (GC) outcomes differ between Asian and
(MSKCC) and Yokohama City University found that the more favorable outcomes for patients with GC at the Japanese institution were attributable to differences in tumor location and T category. 10 A series of two comparisons of GC outcomes at MSKCC with those at Seoul St. Mary's Hospital in South Korea led to contrasting conclusions. While the first study found that survival was greater among Korean patients stage-for-stage, 13 the second, in which there were fewer differences between institutions in surgical approach, found that survival was similar. 11 Finally, only one study has compared outcomes between patients in the US (again at MSKCC) and China (at Beijing Cancer Hospital [BCH]), and indicated that survival outcomes were worse at BCH, even when controlling for stage. 12 To further survey potential differences in GC survival between the US and China, we compared the presentation, treatment, pathology, and outcomes of patients who underwent R0 resection at another high-volume cancer center in China, Fujian Medical University Union Hospital (FMUUH) in Fuzhou, to those of patients treated at MSKCC. 
| MATERIALS AND METHODS

| Data collection
| Follow-up after resection
Follow-up after R0 resection consisted of a history and physical, as well as CT or positron emission tomography (PET)/CT of the chest, abdomen, and pelvis and complete blood counts, chemistry profiles, and esophagogastroduodenoscopy as clinically indicated, every 3 to 6 months for 1 to 2 years, every 6 to 12 months for 3 to 5 years, and then every year thereafter for at least 5 years. For patients who received neoadjuvant and/or adjuvant chemotherapy, CT or PET/CT of the chest/abdomen/pelvis with oral and IV contrast was obtained every 6 to 12 months for the first 2 years, then annually up to 5 years. In the MSKCC data set, disease status at last follow-up was based on retrospective review of medical records and review of the Social Security Death Index. In the FMUUH data set, disease status at last follow-up was based on the information of the Department of Gastric Surgery or the National Statistical Office.
| Statistical analysis
Disease-specific survival (DSS) was measured from the time of surgery to death from GC. Continuous variables were evaluated as means ± standard deviation using t test, and interval values are presented as medians. Differences in proportions between the two countries were compared using the Chi-squared test. DSS was estimated using the Kaplan-Meier method. Survival distributions were compared using the log-rank test. 
| Survival analysis
At MSKCC and FMUUH, median follow-up times were 38 (range, 0-184) and 43 (range, 0-147) months, respectively. The 5-year DSS was 72% at MSKCC, and 60% at FMUUH (P < 0.001; Supporting
Information Table S1 ; Figure 1 illustrates DSS over time). The numbers of deaths from other causes are provided to address potential underestimation of risk of cancer-related death (Supporting Information Table S1 ). At MSKCC the probability of death due to other causes was higher than at FMUUH (10% vs 3%).
To eliminate the potential for biased down-staging due to the more frequent use of preoperative chemotherapy at MSKCC, we compared DSS in patients receiving surgery without preoperative chemotherapy between the two institutions. The 5-year DSS was still higher at MSKCC (80% vs 61%; P < 0.001; Table 2 ; Figure 2A ). Comparing survival within substages and procedures, 5-year DSS was higher at MSKCC for patients with advanced T (T3-T4) and N (N3) category cancer, and for those who underwent proximal or total gastrectomy.
| Identification of factors contributing to DSS
Our unadjusted single-factor analysis identified 10 factors as significantly associated with DSS (Table 3) . Adjusted multivariate analysis narrowed the list of significantly contributing factors to age (P < 0.001), histology (P < 0.001), tumor size (P = 0.006), depth of invasion (P = 0.009), number of metastatic LNs (P < 0.001), number of negative LNs (P < 0.001), gastrectomy type (P < 0.001), and preoperative chemotherapy (P < 0.001), and eliminated institution (P = 0.449; Table 3 ).
Among patients receiving surgery without preoperative chemotherapy, adjusted multivariate analysis identified a similar list Disease-specific survival Table S2 ). Among patients receiving surgery without either pre-or postoperative chemotherapy, fewer factors were identified; compared with the list of factors for the whole population, the only addition was lymphadenectomy (P = 0.025), and the exceptions were tumor size and gastrectomy (Supporting Information Table S3 ).
| DISCUSSION
Here, we show that stage-adjusted survival outcomes are similar for patients with GC at a high-volume institution in China and a similar center in the US. This conclusion contrasts with that of a recent study comparing GC outcomes at another high-volume cancer treatment center in China, BCH, to those at the same US institution (MSKCC), in which survival was worse at the Chinese center, even for patients with the same stage cancer.
12
Many factors may help explain the distinct conclusions of the current study and that of the prior US-China comparison. 12 The most likely contributor is the much greater number of lymph nodes retrieved at FMUUH (median 32 vs 16 at BCH). Greater lymph node retrieval has been associated with better survival in numerous studies, 15, 16 including one in China. 17 Another key difference is that the prior study included patients with fewer than 15 LNs retrieved, which may have resulted in underestimation of N category preferentially among Chinese cases, where retrieval of few lymph nodes was more frequent. 12 Such stage migration would make outcomes appear worse for cancers classified as early-stage but which were actually more advanced.
T A B L E 2 Five-year disease-specific survival in patients receiving surgery without preoperative chemotherapy by subgroup FMUUH (n = 4171) MSKCC (n = 733) The current study has several limitations. This is a retrospective study comparing data from two different institutions in disparate regions of the world, so the analysis is vulnerable to both confounding factors and selection bias despite our best efforts to adjust for differences between the two groups. Our data also spans a time period of 15 years, so treatments may have changed over time, which could impact survival.
Our findings may not be representative of GC outcomes across China. As FMUUH is a university hospital in an urban area that treats 
| 979
T 10, 11 which is possible because of large-scale government-sponsored screening programs. 23, 24 A similar screening program has been implemented in parts of China with especially high GC prevalence 25, 26 ; expanding these efforts could improve nationwide outcomes in the long term. In Asian countries without screening, survival appears to be similar to that in the West, 5 ,27 though few in-depth studies have compared outcomes stage by stage.
While our investigation suggests that GC survival is governed by well-established prognostic variables such as stage and lymph node positivity rather than geography, the disparate findings of these two analyses highlight the need for further investigation to define and understand potential differences in GC presentation, etiology, and treatment among different geographic locations.
| CONCLUSIONS
Marked discrepancies exist in clinicopathologic presentation of patients with GC between high-volume cancer centers in the US and China. After adjusting for relevant prognostic factors, however, stage-specific DSS is similar and is governed by extent of disease after resection. 
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